Navigate Complexities With HIV Therapy

August 2026

Doravirine/islatravir (Idvynso) is a new antiretroviral therapy (ART) that will raise questions about how to treat HIV.

It’s a single-tablet combo nucleoside reverse transcriptase inhibitor (NRTI) plus a non-nucleoside reverse transcriptase inhibitor (NNRTI).

Doravirine/islatravir is only for patients on a stable ART regimen who are virologically suppressed...haven’t failed previous ART...and have no known doravirine resistance.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Immunizations Vaccines in Pregnancy: What’s Recommended and When?
Hypertension Listen for Buzz About Baxdrostat for Resistant Hypertension
Acute Pain Acute Pain Management in Patients on MOUD: A Clinical Guide
Cardiology Look for Prevention Meds After Coronary Bypass Graft Surgery
Education and Training Beyond “Great Job”: Giving Feedback to Grow Learners
Rumor vs Truth Take the Pain out of Debunking Opioid-Related Rumors
HIV & AIDS Navigate Complexities With HIV Therapy
NatMed Spotlight Be Aware of Precautions With Sea Moss Supplements

Navigate Complexities With HIV Therapy

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents